Compound Planning Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX

Key Points

• Compound Planning Inc. invested approximately $244,000 in Royalty Pharma PLC by acquiring 7,838 shares in the first quarter.
• Royalty Pharma has announced a quarterly dividend of $0.22 per share, representing an annualized yield of 2.5%.
• The firm’s recent earnings report showed an EPS of $1.14, exceeding analysts' expectations of $1.10, although revenue fell short at $578.67 million.

Compound Planning Inc. purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 7,838 shares of the biopharmaceutical company's stock, valued at approximately $244,000.

Several other institutional investors also recently made changes to their positions in RPRX. Martingale Asset Management L P acquired a new stake in shares of Royalty Pharma during the 1st quarter worth $436,000. Credit Agricole S A grew its position in Royalty Pharma by 1,701.5% during the first quarter. Credit Agricole S A now owns 125,130 shares of the biopharmaceutical company's stock valued at $3,895,000 after acquiring an additional 118,184 shares during the period. Korea Investment CORP increased its stake in Royalty Pharma by 32.1% during the first quarter. Korea Investment CORP now owns 296,172 shares of the biopharmaceutical company's stock worth $9,220,000 after acquiring an additional 71,900 shares during the last quarter. Summit Securities Group LLC purchased a new position in shares of Royalty Pharma in the 1st quarter worth about $36,000. Finally, Raymond James Financial Inc. lifted its stake in shares of Royalty Pharma by 38.7% in the 1st quarter. Raymond James Financial Inc. now owns 1,086,989 shares of the biopharmaceutical company's stock valued at $33,838,000 after purchasing an additional 303,356 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

Shares of RPRX stock traded up $0.21 during mid-day trading on Wednesday, hitting $36.38. 517,456 shares of the stock traded hands, compared to its average volume of 4,267,085. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The company's 50-day simple moving average is $36.29 and its 200-day simple moving average is $34.11. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $38.00. The firm has a market cap of $21.21 billion, a price-to-earnings ratio of 21.03, a price-to-earnings-growth ratio of 2.35 and a beta of 0.58.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. The firm had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. As a group, equities research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 15th. Royalty Pharma's payout ratio is currently 50.87%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wall Street Zen raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley increased their target price on Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Finally, Citigroup boosted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat.com, Royalty Pharma currently has an average rating of "Buy" and a consensus price target of $48.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.